Land Retained Mandates 60–90 Days before the Market Knows

What happened

A cardiac arrest patient, five weeks post quadruple bypass surgery, arrived at Gateway Regional at 5:02 PM. The hospital diverted the patient to another facility without obtaining state approval, which did not come until 5:37 PM. The patient was rerouted and admitted to the ICU at the receiving hospital. The root cause was financial: the hospital’s payroll bounced, and the CNO told state inspectors she was not sure how many staff were going to show up for the shift. The same CNO admitted she did not know that ambulance diversion required state approval. Parent company American Healthcare Systems, led by CEO Michael Sarian out of Los Angeles, personally loaned $1 million to cover the August 1 payroll. Gateway CEO Joe Ottolino, a veteran hospital executive, was installed recently as part of a new leadership team. The hospital has rewritten its diversion policy in consultation with IDPH, but the underlying problem has not been solved: financial instability driving staffing failures driving patient safety failures. The IJ citation is the regulatory symptom of an operational crisis that extends well beyond one evening.

Probable roles

CNO (the current CNO admitted not knowing diversion required state approval), VP of Nursing, Quality Director, interim CFO or financial restructuring leadership, Director of Emergency Services

Decision makers

CEO Joe Ottolino for operational roles. AHS CEO Michael Sarian for board-level and financial leadership decisions. IDPH Region 4 EMS Coordinator for the regulatory relationship.

Outreach angle

Your CNO told inspectors she did not know ambulance diversion required state approval. A cardiac arrest patient was rerouted because payroll bounced and staff did not come in. The IJ citation is the symptom. The root cause is financial instability driving staffing failures driving patient safety failures. The hospital needs a CNO who has operated under CMS scrutiny before and can rebuild nursing operations while the financial restructuring runs underneath. That profile is specific enough that internal recruitment will not close it.

Value asset

Remediation Leadership Readiness Brief

A financial model quantifying daily patient safety risk during the CMS remediation window, showing the board the cost per day of operating with leadership that has already demonstrated a compliance gap to regulators. Paired with a Peer Remediation Playbook showing how comparable community hospitals separated operational and financial leadership during simultaneous CMS and financial crises to prevent cascading failures.

What happened

Indiana University Health is building a 140-bed hospital in Fort Wayne with six ORs, 17 ED exam rooms, three cardiac cath labs, four endoscopy rooms, and a connected medical office building. Opening is May 2027, nine months away. The system is recruiting 270+ nursing positions across ICU, progressive care, medical-surgical, OR, cath lab, and emergency care. Total staffing will exceed 600 team members and 60 providers. Half of the physician recruits are targeted to be new to northeast Indiana, meaning IU Health is competing with every other Midwest health system for relocation-ready candidates. The system is simultaneously building clinical training programmes, residency opportunities, and tuition support to attract the pipeline. Dr. Greg Johnson, Chief Physician Executive of Growth Markets, and John Bowen, Chief Growth Markets Officer, are leading recruitment and operational planning. Nine months from a facility opening of this scale means the executive leadership team — Hospital CEO or President, CNO, CMO, COO, ED Director, and surgical services leadership — is being finalised now. The physician leadership and department head searches should already be underway.

Probable roles

Hospital CEO or President (new facility), CNO, CMO, COO, ED Director, Surgical Services Director, Cardiac Cath Lab Director, Nursing Directors (ICU, Med-Surg, OR, ED), Director of Imaging, Director of Lab Services, 60+ physician recruits across multiple specialties

Decision makers

Dr. Greg Johnson, Chief Physician Executive of Growth Markets. John Bowen, Chief Growth Markets Officer. IU Health system leadership for C-suite appointments at the new facility.

Outreach angle

You are nine months from opening a 140-bed hospital with six ORs and three cath labs. The nursing pipeline is underway with 270+ positions in recruitment, but the physician and executive leadership team determines whether this facility opens on time and operates at the clinical standard IU Health’s brand demands. Half your physician targets are new to northeast Indiana, which means you are competing with every other health system in the Midwest for the same relocation-ready candidates. The search firms positioned to fill CMO, ED Director, and cath lab leadership now are the ones you will call when the volume ramps post-opening.

Value asset

Go-Live Facility Staffing Blueprint

A milestone-mapped hiring sequence showing when to recruit each executive and physician leadership role relative to the May 2027 opening, benchmarked against how comparable 100–150 bed new hospital builds in the Midwest structured their leadership recruitment at 9, 6, and 3 months pre-opening. Ensures the hiring timeline does not become the constraint on the facility readiness timeline.

What happened

A leadership crisis cascaded through one of South Florida’s largest health systems in a single week. Caitlin Stella, CEO of Joe DiMaggio Children’s Hospital, was removed as part of a reorganisation, and CMO Dr. Ronald Ford followed within 48 hours. At Memorial Hospital West, CEO Joseph Stuczynski retired and COO Judy Frum was terminated. Stephen Demers moved from Memorial Miramar to fill the West vacancy, creating a second CEO opening at Miramar, now filled by Felicia Turnley. The system itself is still operating under interim CEO Shane Strum, who simultaneously serves as CEO of Broward Health System. That is at least five leadership seats that changed hands in one week, with new leaders at two hospitals who will each be assembling their own teams over the next 90 days. This is not a single departure. It is a system-wide leadership reset affecting three facilities, two of which now have newly appointed presidents who need to build VP and director-level teams from their own networks.

Probable roles

CEO (interim, system-level), CMO (Joe DiMaggio Children’s), COO (Memorial West), VP-level leadership under each new hospital CEO across both Memorial West and Memorial Miramar

Decision makers

Shane Strum, interim system CEO. Stephen Demers at Memorial West, building his leadership team now. Felicia Turnley at Memorial Miramar, building hers now.

Outreach angle

Five leadership seats changed hands in one week across three facilities, and the system itself is still running under an interim CEO who also runs another health system. Each new hospital CEO will build their own team in the next 90 days, which means VP and director-level searches are coming before those roles are even posted. The firms that map the talent market now will be positioned when those searches go live.

Value asset

Pre-Market Talent & Compensation Benchmark

A local talent map for South Florida healthcare executives across the VP and director-level roles most likely to open in the next 90 days under two newly appointed hospital presidents, benchmarked against current market compensation to ensure offers are competitive in a market where multiple leadership seats are open simultaneously and candidates have options.

What happened

UChicago Medicine hired four senior neurosurgeons at once. This is not backfill. It is a full programme build led by department chair Mohamad Bydon. The department recruited a new spine chief, neuro-oncology chief, trauma chief, and vascular chief in a single quarter, which means the programme leadership is being constructed from the top down. The system has simultaneously installed robotic spine surgery capabilities and intraoperative MRI, signalling that the capital investment in infrastructure is running in parallel with the physician recruitment. The goal is a national referral programme for complex neurosurgical cases, which means additional hires beyond the initial four are likely as case volume grows. Academic medical centres at this level recruit fellowship-trained neurosurgical subspecialists through retained search, because the candidate pool willing to join an academic programme — with its governance complexity, teaching obligations, and competitive Chicago market — is extremely narrow.

Probable roles

Neurosurgeons (additional hires likely as the programme scales), spine surgeons, neuroscience subspecialists, neurosurgical OR nursing leadership, neuro-ICU nursing leadership

Decision makers

Department Chair Mohamad Bydon, programme architect and hiring authority for all neurosurgery faculty. UChicago Medicine system leadership for institutional approvals and credentialing.

Outreach angle

Hiring four neurosurgeons at once is a programme build, not backfill. A department chair who just installed new chiefs in spine, neuro-oncology, trauma, and vascular neurosurgery within a single quarter is building a national referral programme, which means the next wave of hires is already in planning. The subspecialty profiles needed — fellowship-trained neurosurgeons willing to join an academic programme in a competitive Chicago market — represent one of the narrowest candidate pools in physician recruitment. A search firm that already has relationships in academic neurosurgery can shorten the timeline from nine months to four.

Value asset

Pre-Market Talent & Compensation Benchmark

A candidate market snapshot showing the total passive pool of fellowship-trained neurosurgical subspecialists currently in academic settings nationally, with real-time compensation benchmarks across comparable academic medical centres. Gives the department chair a data-backed view of exactly how many candidates exist for each subspecialty chief role and what it takes to move them.

What happened

Wellspring Capital acquired Summit from MSouth Equity Partners in March 2025 for undisclosed terms, with Houlihan Lokey as exclusive financial advisor. That was Summit’s third private equity recapitalisation in seven years. Within months of the Wellspring acquisition, Summit completed the Southeast Neurology & Pain Management add-on, expanding into the Florida Panhandle. The platform now spans 55 clinics and 21 ASCs across Georgia, North Carolina, South Carolina, Florida and Tennessee. Wellspring’s current portfolio companies employ nearly 60,000 people globally and generated aggregate revenues exceeding $4.5 billion in 2024; over the past 25 years the firm has made more than 50 platform investments. The pace of acquisition means the integration and recruitment cycle at Summit is continuous. CEO and founder Dr. Amit Patel has described the model as physician-centric, combining hospital affiliations with ASC ownership opportunities for physicians, which has driven the company’s sustained growth over the past decade.

Probable roles

Spine surgeons, interventional pain physicians, ASC medical directors, regional operations directors, practice managers at acquired locations, integration leadership

Decision makers

Dr. Amit Patel, CEO and Founder of Summit Spine & Joint Centers, is the entry point for physician recruitment. Naishadh Lalwani, Managing Partner at Wellspring Capital Management and the deal lead, is the entry point for platform strategy.

Outreach angle

Three acquisitions in three years across five states means you are running integration and physician recruitment simultaneously at every stage. Each new practice you absorb needs its medical director reviewed, its operations leadership assessed, and its surgeon roster evaluated for growth potential. The ASC portfolio alone, 21 centres, creates a continuous need for credentialed surgeons across multiple geographies. A search firm that understands PE roll-up dynamics in spine and pain management can map physician candidates across your expansion corridor before each acquisition closes, so recruitment starts on day one of integration, not day 90.

Value asset

Post-Acquisition Executive Retention & Integration Checklist

A 90-day governance framework mapping leadership retention risk and physician integration priorities across each newly acquired practice, including which medical director and operations roles historically turn over within the first two quarters post-close, and where proactive succession planning prevents disruption to patient volume and ASC utilisation.

What happened

This is the facility formerly known as Catalent Bloomington, acquired by Novo Nordisk. It has now received Official Action Indicated classification in back-to-back years, which means a full year of investment in remediation failed to satisfy the FDA. Eight observations in April included contamination that Novo described as detected through normal manufacturing controls, but the FDA classified the finding as an unacceptable state of compliance. The downstream impact is significant: Scholar Rock removed the facility from its BLA for a spinal muscular atrophy therapy and is proceeding with a backup fill-finish site. Regeneron has also been affected by quality issues at this facility in prior years. For the CDMO itself, repeat OAI means client confidence is eroding. Companies relying on Bloomington for commercial fill-finish are now looking for alternatives, and the quality leadership installed after the first OAI has not delivered results. The VP of Quality, Director of Sterility Assurance, and potentially the Site Director are all under board-level scrutiny. The next inspection cycle will determine whether this facility can continue operating as a commercial fill-finish CDMO.

Probable roles

VP of Quality (remediation track record required), Director of Sterility Assurance, Site Director, Director of CAPA, Director of Quality Systems, Quality Remediation Lead (interim to permanent)

Decision makers

Novo Nordisk CDMO division leadership, which holds site-level hiring authority. Scholar Rock CEO David Hallal, an affected client needing an alternative fill-finish partner. Regeneron leadership, an affected client with a prior CRL linked to this site.

Outreach angle

Your facility has received OAI classification two years in a row. The quality leadership installed after the first finding has not remediated the issues. Two biopharma clients have publicly pulled or restructured their filings because of your site’s compliance status. The next inspection cycle will determine whether this facility can continue operating as a commercial fill-finish CDMO, and the FDA will be looking specifically at whether the quality leadership team has changed and whether the new team has a demonstrable track record of FDA remediation at comparable sterile manufacturing sites.

Value asset

Remediation Leadership Readiness Brief

A financial model quantifying client revenue at risk per month of continued OAI status, showing how much commercial fill-finish business is at stake if the next FDA inspection does not result in a classification upgrade. Paired with a Peer Remediation Playbook showing how comparable CDMO fill-finish sites restructured quality leadership after repeat OAI, and the timeline from new leadership installation to successful re-inspection.

What happened

Cogent is executing something rare in biopharma: three simultaneous product launches from a single company. The GIST indication has a Priority Review PDUFA on November 30, meaning the FDA decision is less than four months away. A second PDUFA follows on December 30 for non-advanced systemic mastocytosis. A third NDA for advanced SM was submitted on the last day of June 2026. The company has $792M in cash after opening a $400M ATM facility, signalling confidence in approval. The commercial build is visible in the financials: G&A more than doubled year-over-year to $31.8M, reflecting field force, patient access infrastructure, and market access spend landing on the P&L six months before the first prescription. The company has hired and onboarded its full customer-facing organisation including clinical account managers, patient access navigators, patient educators, and medical affairs staff. CEO Andrew Robbins, CFO John Green, and CMO Dr. Jessica Sachs all adopted 10b5-1 trading plans in July. Despite the commercial team being largely built, launching two indications simultaneously in Q4 2026 while preparing a third will require additional launch operations, field medical, and post-approval roles.

Probable roles

Regional Sales Directors, District Managers, Director of Sales Training, Director of Launch Operations, Field Medical Directors, Director of Distribution and Trade, VP of Patient Services, Director of Pharmacovigilance, Head of Medical Information, Field Reimbursement Managers

Decision makers

CEO Andrew Robbins for strategic commercial roles. CFO John Green for finance and operations. CMO Dr. Jessica Sachs for medical affairs and field medical roles.

Outreach angle

Three NDAs pending with two PDUFA dates within 30 days of each other is an unprecedented launch execution challenge. The commercial organisation is hired, but launching two indications simultaneously in Q4 2026 while preparing a third means every gap in the field team, every delay in training, and every missing regional leader compounds across all three programmes. The firms positioned to fill launch operations and post-approval roles before November are the ones that will be in the room when the approval announcements drop.

Value asset

Go-to-Market Leadership Blueprint

A milestone-to-hire sequence map showing the exact roles needed pre-PDUFA versus post-approval for a dual-indication simultaneous launch, benchmarked against peer rare disease companies that launched multiple indications within 90 days. Ensures the commercial team is not scrambling to fill post-approval roles after the FDA decision, when every other company is also hiring.

What happened

CereVasc closed an oversubscribed $85M Series C with a strategic investor syndicate that includes two of the largest medical device companies in the world: Johnson & Johnson Innovation and Medtronic. Bain Capital Life Sciences and Piper Sandler Merchant Banking also participated. That investor composition is a signal on its own: when J&J and Medtronic both invest in the same MedTech company, they are either validating the technology for potential future acquisition or positioning for a commercial partnership. The funding supports the STRIDE pivotal trial for the eShunt System, a minimally invasive implant designed to treat Normal Pressure Hydrocephalus, a condition currently treated with traditional shunts requiring open brain surgery. CEO Dan Levangie has described the eShunt as addressing a significant unmet need with a less invasive approach. The PMA pivotal trial means the company is 18–24 months from a potential FDA decision, and commercial scale-up preparation is explicitly part of the funding use. VP of Regulatory Affairs, VP of Clinical Affairs and VP of Commercial should all be in place or in active search 12–18 months before anticipated approval.

Probable roles

VP of Regulatory Affairs, VP of Clinical Affairs, VP of Commercial, Director of Market Access and Health Economics, Director of Medical Education (surgeon training programme), Director of Clinical Operations (pivotal trial management), VP of Quality, Field Clinical Specialists

Decision makers

Dan Levangie, CEO, who drives all leadership hiring at this stage of the company. For strategic roles such as VP Commercial and VP Regulatory, the board and lead investors — Bain Capital Life Sciences and Piper Sandler — will have input on candidate selection.

Outreach angle

J&J Innovation and Medtronic both invested in your Series C. When two of the three largest device companies in the world validate the same technology, the candidate market pays attention. Your PMA pivotal trial is underway, which means you are 18–24 months from a potential FDA decision and need your regulatory, clinical, and commercial leadership in place before the data reads out. The VP of Regulatory Affairs who manages a PMA submission for a neurovascular implant is a narrow profile, and the best candidates are currently employed at companies that may be your future acquirers or partners. A search firm that can navigate those dynamics discreetly brings candidates you would never see through a job posting.

Value asset

Go-to-Market Leadership Blueprint

A milestone-to-hire sequence showing when to place VP of Regulatory Affairs (pre-PMA submission), VP of Clinical Affairs (during the pivotal trial), and VP of Commercial (12–18 months pre-approval) relative to the STRIDE timeline and anticipated FDA review. Benchmarked against comparable neurovascular MedTech companies that moved from pivotal trial to PMA approval, showing team size and leadership structure at each stage.

What happened

Xcellon is a company that launched in 2025 and just made a transformational acquisition: NextCure’s entire GMP biologics manufacturing facility in Beltsville, Maryland. This is not an incremental expansion. It is a company that went from development-stage CRDMO to end-to-end clinical manufacturer in a single transaction. The facility includes two 1,000L single-use bioreactors, a bioconjugation suite — their core specialty in ADCs, bispecific antibodies, and T-cell engagers — robotics-enabled process development, and full analytical capabilities. GMP operations are planned for December 2026, which means the leadership team to run the facility needs to be in place within the next 90 days. CEO Abhishake Chhibber described this as building one of the nation’s premier CRDMOs for bioconjugates and complex biologics. The team has collectively launched 8 products, filed 20+ INDs, and includes alumni from Lonza, Abzena, Amgen, MedImmune, AstraZeneca, BioNTech, Seattle Genetics, and Immunomedics.

Probable roles

Site Director, VP of Quality, Director of Manufacturing, Director of Analytical Development, Director of Process Development, Director of Validation, Quality Control Director, Batch Release Director

Decision makers

Abhishake Chhibber, CEO. At a company with 11–50 employees the CEO is the sole hiring authority for all leadership roles, so all outreach goes directly to him.

Outreach angle

You acquired a 40,000 sq ft GMP facility and plan to begin operations in December 2026. That is four months to hire and onboard a Site Director, VP of Quality, Director of Manufacturing, and Director of Validation, all roles that require candidates with hands-on GMP biologics experience and a track record satisfying FDA pre-approval inspections. The talent pool for bioconjugate and ADC manufacturing leadership is one of the smallest in the industry, and every month of delay between now and December compresses your validation timeline.

Value asset

GMP Facility Leadership Hiring Sequence

A milestone-mapped timeline showing when each leadership role — Site Director, VP Quality, Director of Manufacturing, Director of Validation — must be filled relative to the December 2026 GMP operations start date, anchored to equipment qualification, IQ/OQ/PQ validation, and first engineering batch milestones. Ensures the hiring sequence does not become the bottleneck in the facility readiness timeline.

What happened

AusperBio has raised $360 million in two years, which puts it in the upper tier of clinical-stage biopharma funding. The company describes itself as near-commercial, a term that signals the transition from R&D-led organisation to one that needs commercial infrastructure. The Phase 3 registrational programme for AHB-137 is the lead asset, and the Series C explicitly funds commercialisation readiness alongside continued development of AHB-171, an siRNA candidate on their proprietary Au-HALO delivery platform. CEO Dr. Guofeng Cheng described this as an inflection point. RA Capital’s participation adds institutional validation. A company at this stage, with this level of capital, preparing for commercial launch in hepatitis B — a global market with complex access dynamics — needs to begin building its commercial leadership team now. The CCO, VP of Market Access, VP of Medical Affairs, and Head of Commercial Operations are all roles that should be placed 12–18 months before anticipated approval. At $360M raised and Phase 3 underway, the capital is committed and the hiring is funded.

Probable roles

Chief Commercial Officer, VP of Market Access, VP of Medical Affairs, VP of Sales, Head of HEOR, MSL Director, Director of Commercial Operations, VP of Alliance Management (if a partnership or co-commercialisation follows)

Decision makers

CEO Dr. Guofeng Cheng for C-suite commercial roles. Board members and lead investors for CCO-level searches.

Outreach angle

$360 million raised in two years and a Phase 3 registrational programme underway means the board has committed to commercialisation. The question is no longer whether the company will build a commercial team, it is when and who leads it. Hepatitis B is a global market with complex payer dynamics, established competition, and a patient population that requires a sophisticated medical affairs and market access strategy. The CCO and VP of Market Access need to be in place 12–18 months before anticipated approval to design the launch architecture.

Value asset

Go-to-Market Leadership Blueprint

A candidate market snapshot showing the total passive pool of executives with HBV or infectious disease commercial launch experience, with real-time compensation benchmarks for CCO and VP Market Access roles at comparable near-commercial biopharma companies. Gives the CEO and board a data-backed view of how narrow the candidate market is and what compensation structures are actually closing offers at this stage.